GigaDevice to Showcase Innovations for Accelerated IoT and Automotive Sectors at Electronica 2024
GigaDevice, a leading semiconductor company specializing in Flash Memory, 32-bit Microcontrollers (MCUs), Sensors, Analog products and solutions, is set to unveil its latest technological masterpieces and present a showcase of innovations specifically designed to drive the rapid growth of the IoT and automotive sectors into the future at Electronica 2024, which will take place from November 12 to 15 in Munich, Germany. Please pay us a visit at Booth 209, Hall4 to experience these advancements.
- Enhance your energy management
AI-Based AFCI Solution for Solar System by GigaDevice features the high-performance GD32H7 series MCU. With a sampling rate of 500KSPS, it supports real-time AI inference capabilities for arc detection across up to 12 ADC channels. The algorithm uses a deep convolutional neural network, capable of real-time detection with 1024, 2048, and 4096 sampling points, occupying only 1.7KB of Flash. Each inference takes less than 0.6ms, ensuring immediate response to DC arcing events. The model can also be compatible with data collected by different hardware and is compatible with photovoltaic string currents of 0 to 40A, achieving 100% accuracy. It also includes data acquisition tools and a one-click training feature for user convenience.
Bidirectional energy storage inverter solution based on the GD32G5x3 series MCU from GigaDevice supports off-grid discharge and grid-connected charging functions. Using two GD32G5x3 MCUs, it controls a three-level architecture (LLC + Buck/Boost + inverter/PFC) for high efficiency and stability. The LLC operates at 100kHz, while the Boost/Buck and inverter/PFC components run at 20kHz. In off-grid power supply mode, the battery voltage (ranging from 20 to 27.2V) can be inverted to 220VAC main voltage, with a maximum power of up to 1kW. In grid-connected charging mode, 220VAC main voltage is rectified to 24V DC voltage to charge the battery pack, with a maximum power of up to 500W. This solution is ideal for portable energy storage applications like outdoor camping, aerial photography, mobile offices, emergency charging, and medical rescue.
- Boost Your AIoT capabilities
The GD25UF ultra-low power flash is tailored for advanced SoCs without 1.8VIO support, operating at 1.2VIO and offering 50-70% power savings in Low Power Mode. Suited for wearables, IoT devices, tablets, and other battery-powered applications, this series enhances energy efficiency in devices using 14nm or smaller process nodes. Additionally, the high-speed GD25LT/LX series achieves 400Mbit/s throughput, facilitating rapid code execution in IoT applications.
The AI-Based Voice Recognition demonstration showcases a real-time speech keyword detection solution utilizing Sensory's speech recognition algorithm, implemented on the GD32H7 MCU. The design is based on the GD32H759i-Eval Board with a main processing frequency of up to 600MHz, providing powerful computational capabilities. Additionally, it supports up to 3840KB of Flash memory and 1MB of SRAM, enabling efficient storage and handling of speech data. This setup demonstrates the potential for robust, high-speed keyword detection in embedded systems.
Matter Solution equipped by G32VW553 MCU which supports Wi-Fi 6 and Bluetooth LE 5.2. This microcontroller excels in edge processing and connectivity, making it suitable for a wide range of wireless applications such as smart home devices, systems, industrial internet, and communication gateways. Additionally, its affordability makes it an ideal choice for cost-sensitive scenarios like office equipment, payment terminals, and various IoT devices.
- Drive Automotive Innovation Forward
GigaDevice offers comprehensive automotive Flash products, including 2Mb to 2Gb GD25 NOR Flash and 2/4Gb GD5F SPI Nand Flash, which are manufactured using 55nm and 38nm process nodes. The new GD25LX Octal Flash product with 128Mb and 64Mb to address the growing needs of high-speed memory requirements. GD25 and GD5F families cater to various automotive applications, such as ADAS, infotainment, and digital cockpit/cluster systems. Those automotive Flash are AEC-Q100 qualified and produced at multiple sites to support global Tier 1 suppliers and automotive OEMs, ensuring a robust supply chain.
GigaDevice's new GD32A7 series automotive-grade MCUs surpass the performance of previous Arm® Cortex®-M4/M33 generations with an ultra-high-performance Arm® Cortex®-M7 core. Offering variants like GD32A71x/GD32A72x/GD32A74x, these MCUs deliver excellent performance, enhanced security, and a rich set of peripheral interfaces. They are designed for various automotive applications, including body domain control, telematics, lighting, battery management, on-board chargers, and DC-DC converters, expanding GigaDevice's automotive products portfolio.
Body Domain Control Solution based on GD32A72x MCU, supports keyless entry (UWB or PEPS) and anti-pinch algorithms for window operation. It provides a super-wide input voltage range of 7V-18V, supports 20 channels of high-side drive output and 24 channels of low-side drive output, along with CANFD and LIN communications protocols.
BMS solution designed with the GD32A74x MCU, operates at 160MHz in single lockstep core mode, with up to 4MB of Flash and 512KB of SRAM. It features an expandable main control board interface for connecting battery cell monitors and pack monitor boards through isolated bridge ICs. Compatible with various AFE & bridge chip solutions, it includes 8 high-side switches, 6 low-side switches with current detection and diagnosis functions. The solution also integrates a local network wake-up CAN transceiver, two high-speed CANFD transceivers with fault protection, and supports CAN wake-up and daisy-chain signals. Additionally, an integrated RTC chip enables timed wake-ups, and the system features collision signal input and interlock signal PWM sampling output.
Come and visit GigaDevice at booth 209, hall 4 in person, and join our speech at Embedded Systems Design Forum (Booth A5-351).
- Nov.14, Thursday, 3:40PM-4:10PM, Supporting your AIoT Anywhere with Arm-Based GD32 Microcontrollers
View source version on businesswire.com: https://www.businesswire.com/news/home/20241111632306/en/
Contacts
Phone number: + 86 (010) 8288 1196
Email address: marcom@gigadevice.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Nemluvio ® (Nemolizumab) for Patients with Moderate-to-Severe Atopic Dermatitis13.12.2024 23:09:00 CET | Press Release
Galderma (SWX:GALD) today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Nemluvio® (nemolizumab) for the treatment of patients 12 years and older with moderate-to-severe atopic dermatitis, in combination with topical corticosteroids (TCS) and/or calcineurin inhibitors (TCI) when the disease is not adequately controlled with topical prescription therapies. This follows the recent U.S. FDA approval of Nemluvio for subcutaneous injection for the treatment of adults with prurigo nodularis in August 2024.12 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241213562840/en/ Atopic dermatitis affects more than 230 million people worldwide, impacting approximately 7% of people in the U.S.2-4 Often reported as one of patients’ most problematic symptoms, 87% of people with atopic dermatitis say they are seeking freedom from itch, with speed of itch relief therefore also prioritized by both patient
Experian’s 2024 Global Identity & Fraud Report Spotlights Huge Growth in Highly Personalized GenAI-Driven Fraud Attacks13.12.2024 15:00:00 CET | Press Release
Today, Experian announced its 2024 Global Identity & Fraud Report that provides a comprehensive view of the consumer and business response to the latest fraud patterns and fraud‑mitigation strategies in the worldwide financial services sector. The report offers combined insights from more than 1,000 businesses and fraud leaders globally, as well as 4,000 consumers, focusing on fraud management and the digital experience. Among its key insights, the report casts a bright spotlight on three factors driving the fast-evolving fraud landscape: the huge growth in Generative Artificial Intelligence (GenAI) technologies, changing government regulations, and the push among businesses to provide consumers with secure and convenient digital experiences. In response to these factors, the report’s findings revealed that businesses intend to increase fraud budgets driven by investments in AI and machine learning technologies. “Unlike other issues facing financial services companies, fraud operates b
Capcom Announces Onimusha Way of the Sword , Marking the First New Title in the Series in Over 20 Years! Work on an Okami Sequel Project Begins!13.12.2024 14:00:00 CET | Press Release
Capcom Co., Ltd. (TOKYO:9697) today announced that Onimusha Way of the Sword, the first new title in the Onimusha series in over 20 years, is scheduled to be released, while work on an Okami sequel project has also started. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241213232085/en/ Onimusha Way of the Sword (Graphic: Business Wire) The Onimusha series consists of swordplay action games where players assume the role of warriors with the superhuman powers of the Oni and fight against monsters bent on world domination. Onimusha Way of the Sword, scheduled to be released globally in 2026, is a Japanese-inspired dark fantasy game set at the beginning of the Edo period in Kyoto, which has been eerily transformed by clouds of Malice. In the game, the samurai protagonist is equipped with the Oni Gauntlet and engages in epic sword battles with the grotesque and otherworldly creatures known as Genma. Capcom hopes that players loo
BrightPath Bio and Cellistic Announces Process Development and Manufacturing Collaboration for Phase 1 Clinical Trial of iPSC-derived BCMA CAR-iNKT cell13.12.2024 13:51:00 CET | Press Release
BrightPath Bio (Tokyo Stock Exchange Growth 4594, “BrightPath”), a pioneer in iPS cell-derived Natural Killer T (“NKT”) cell therapy, and Cellistic, a leader in advanced iPS cell therapy manufacturing, today announced a process development and manufacturing agreement to advance BrightPath’s novel allogeneic CAR-T cell therapy platform, utilizing iPSC-derived NKT cells for clinical trials. The strategic collaboration includes the use of Cellistic's innovative 3D bioreactor-based manufacturing platform, Echo, to enable GMP-compliant, clinical-scale manufacturing of iPSC-derived BCMA-targeting CAR-NKT cells for Phase 1 multiple myeloma trial; establishing BrightPath as a first mover in this emerging field. “The use of NKT cells as effectors in allogeneic CAR-T therapy represents a promising strategy, offering not only direct cytotoxicity but also indirect anti-tumor activity through the priming of host CD8+ T cells—a mechanism expected to evade host immune rejection and to enhance the dur
CHMP Recommends Approval of Galderma’s Nemolizumab for Moderate-to-Severe Atopic Dermatitis and Prurigo Nodularis in the European Union13.12.2024 07:00:00 CET | Press Release
Galderma today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion and recommended granting the marketing authorization of nemolizumab for the treatment of both atopic dermatitis and prurigo nodularis in the European Union (EU). The CHMP has recommended nemolizumab’s approval for subcutaneous use for the treatment of moderate-to-severe atopic dermatitis in patients aged 12 years and older who are candidates for systemic therapy, and for subcutaneous use for the treatment of adults with moderate-to-severe prurigo nodularis who are candidates for systemic therapy. This follows its approval for the treatment of adults with prurigo nodularis by the United States (U.S.) Food and Drug Administration (FDA) in August 2024.14 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241212936857/en/ Atopic dermatitis is a common, chronic, and flaring infl
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom